Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)

Verdict

Headline leans bullish. We score RARE +1.00 across three claims.

Score confirms the headline.

Headline says

Leans bullish

From its wording — no explicit rating

=

Expected · RARE

+1.00strongly bullish